Significant news last week included Vertex Pharmaceuticals dropping development of its acute pain candidate VX-993 following ...

Biotech start-ups around the world are still able to find sufficient backing to put sizeable rounds together, even in these ...

French vaccines developer Valneva announced that the US Food and Drug Administration (FDA) has removed its recommended pause ...

US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA ...

The cancer immunotherapy market is bracing for its next growth phase as bispecific T-cell engagers gain momentum, according ...

US biotech Iovance Biotherapeutics is cutting 19% of its workforce due to slower-than-expected launch of its ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...

Danish biotech Genmab (Nasdaq: GMAB) posted second-quarter revenue of $925 million, up 19% from a year earlier, driven by ...

German family-owned pharma major Boehringer Ingelheim and New York-based Click Therapeutics today announced that the pivotal ...

US artificial intelligence drug discovery firm Chai Discovery has secured $70 million in Series A funding, drawing backing ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...